UNITED THERAPEUTICS Corp Total Revenue

• UNITED THERAPEUTICS Corp showed an increase of +10.6% in Total Revenue from 2024 to 2025.
• This data is from UNITED THERAPEUTICS Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
• XBRL data for this metric is available from 2008 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2013: $280.61 million | Q3 2013: $302.23 million | Q4 2013: $289.02 million | Q1 2014: $289.40 million | Q2 2014: $322.80 million | Q3 2014: $329.95 million | Q4 2014: $346.36 million | Q1 2015: $327.50 million | Q2 2015: $347.20 million | Q3 2015: $386.20 million | Q4 2015: $404.90 million | Q1 2016: $369.00 million | Q2 2016: $412.60 million | Q3 2016: $408.20 million | Q4 2016: $409.00 million | Q1 2017: $370.50 million | Q1 2017: $370.50 million | Q2 2017: $444.60 million | Q2 2017: $444.60 million | Q3 2017: $445.50 million | Q3 2017: $445.50 million | Q4 2017: $464.70 million | Q1 2018: $389.20 million | Q1 2018: $389.20 million | Q2 2018: $444.50 million | Q2 2018: $444.50 million | Q3 2018: $412.70 million | Q3 2018: $412.70 million | Q1 2019: $362.60 million | Q2 2019: $373.60 million | Q3 2019: $401.50 million | Q1 2020: $356.30 million | Q2 2020: $362.00 million | Q3 2020: $380.10 million | Q1 2021: $379.10 million | Q2 2021: $446.50 million | Q3 2021: $444.70 million | Q1 2022: $461.90 million | Q2 2022: $466.90 million | Q3 2022: $516.00 million | Q1 2023: $506.90 million | Q2 2023: $596.50 million | Q3 2023: $609.40 million | Q1 2024: $677.70 million | Q2 2024: $714.90 million | Q3 2024: $748.90 million | Q1 2025: $794.40 million | Q2 2025: $798.60 million | Q3 2025: $799.50 million.
• Over the full 20 years of available data (2008 to 2025), UNITED THERAPEUTICS Corp's Total Revenue has grown by 1,030.6%.
• Historical annual values: Fiscal year 2025: $3.18 billion | Fiscal year 2024: $2.88 billion | Fiscal year 2023: $2.33 billion | Fiscal year 2022: $1.94 billion | Fiscal year 2021: $1.69 billion | Fiscal year 2020: $1.48 billion | Fiscal year 2019: $1.45 billion | Fiscal year 2018: $1.63 billion | Fiscal year 2017: $1.73 billion | Fiscal year 2017: $1.73 billion | Fiscal year 2016: $1.60 billion | Fiscal year 2016: $1.60 billion | Fiscal year 2015: $1.47 billion | Fiscal year 2014: $1.29 billion | Fiscal year 2013: $1.12 billion | Fiscal year 2012: $916.08 million | Fiscal year 2011: $743.18 million | Fiscal year 2010: $592.90 million | Fiscal year 2009: $358.88 million | Fiscal year 2008: $281.50 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026